LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

31-10-2017

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom. LeadArtis is a partner in the Immunostimulatory Agonist Antibodies for Cancer Therapy effort, a 6.9M€ funding initiative which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom). The IACT program aims to translate the agonist IS-Ab concept into immune oncology treatments (http://www.iact-project.eu/). Two ongoing clinical trials are pivotal to bring forward the pre-clinical Proof of Concept. Analogous SME-driven effort aims at the development of 2nd generation agonist IS-Abs with superior therapeutic index. LeadArtis is applying its Biespecific TrimerbodyTM technology for the generation of novel tumor targeting immune stimulating multivalent antibodies.

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...